Skip to main content
Top
Published in: Annals of Surgical Oncology 12/2019

01-11-2019 | Cystectomy | Urologic Oncology

Prognostic Role of the Immunoscore for Patients with Urothelial Carcinoma of the Bladder Who Underwent Radical Cystectomy

Authors: Xiang-Dong Li, MD, Chao-Wen Huang, MD, Ze-Fu Liu, MD, Li-Juan Jiang, MD, Jie-Wei Chen, MD, Dan Xie, MD, PhD, Fang-Jian Zhou, MD, PhD, Hui-Ming Lu, MD, Zhuo-Wei Liu, MD, PhD

Published in: Annals of Surgical Oncology | Issue 12/2019

Login to get access

Abstract

Background

Increasing evidence suggests that cancer progression is strongly influenced by the host immune response, which is represented by immune cell infiltrates. The T-lymphocyte-based Immunoscore is reported to be a reliable prognostic factor in colon cancer, but its significance in urothelial carcinoma of the bladder (UCB) is at an early stage of exploration. This study aimed to determine whether the tumor immune infiltrate, as evaluated by the Immunoscore, could act as a useful prognostic marker for UCB patients who have undergone radical cystectomy (RC).

Methods

In this study, immunohistochemistry was used to examine the Immunoscore of 221 UCB patients who underwent RC. The Immunoscore of the patients was determined by the densities of CD3+ and CD8+ T cells at the tumor center and the invasive margin.

Results

A highly significant association between a low Immunoscore and a shortened patient survival (P < 0.001, log-rank test) was demonstrated. In different subsets of UCB patients, a low Immunoscore also was a prognostic indicator of pT ≤ 2, pN(–)-status tumors, negative vascular invasion, or both (P < 0.05). Importantly, the Immunoscore together with the patient’s pT status provided significant independent prognostic parameters in the multivariate analysis (P < 0.05). Furthermore, a significant correlation (P = 0.003) of a low Immunoscore with an increased UCB labeling index of Ki-67 (a cell proliferation marker) was observed in this UCB cohort.

Conclusions

The findings suggest that the Immunoscore, as examined by immunohistochemistry, might serve as a novel prognostic marker for UCB patients who have undergone RC.
Literature
1.
go back to reference Jacobs BL, Lee CT, Montie JE. Bladder cancer in 2010: how far have we come? CA: Cancer J Clin. 2010;60:244–72. Jacobs BL, Lee CT, Montie JE. Bladder cancer in 2010: how far have we come? CA: Cancer J Clin. 2010;60:244–72.
2.
go back to reference Abdollah F, Sun M, Schmitges J, et al. Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy. BJU Int. 2012;109:1147–54.CrossRef Abdollah F, Sun M, Schmitges J, et al. Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy. BJU Int. 2012;109:1147–54.CrossRef
3.
go back to reference Witjes JA, Comperat E, Cowan NC, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65:778–92.CrossRef Witjes JA, Comperat E, Cowan NC, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65:778–92.CrossRef
4.
go back to reference Sternberg CN, Bellmunt J, Sonpavde G, et al. ICUD-EAU international consultation on bladder cancer 2012: chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2013;63:58–66.CrossRef Sternberg CN, Bellmunt J, Sonpavde G, et al. ICUD-EAU international consultation on bladder cancer 2012: chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2013;63:58–66.CrossRef
5.
go back to reference Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol. 2001;19:666–75.CrossRef Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol. 2001;19:666–75.CrossRef
6.
go back to reference Herr HW, Faulkner JR, Grossman HB, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004;22:2781–9.CrossRef Herr HW, Faulkner JR, Grossman HB, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004;22:2781–9.CrossRef
7.
go back to reference Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors. UICC International Union Against Cancer. 8th ed. Chichester, UK: Wiley-Blackwell; 2017. Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors. UICC International Union Against Cancer. 8th ed. Chichester, UK: Wiley-Blackwell; 2017.
8.
go back to reference Prasad SM, Decastro GJ, Steinberg GD. Urothelial carcinoma of the bladder: definition, treatment, and future efforts. Nat Rev Urol. 2011;8:631–42.CrossRef Prasad SM, Decastro GJ, Steinberg GD. Urothelial carcinoma of the bladder: definition, treatment, and future efforts. Nat Rev Urol. 2011;8:631–42.CrossRef
9.
go back to reference Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer: a current perspective. Nat Rev Urol. 2014;11:153–62.CrossRef Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer: a current perspective. Nat Rev Urol. 2014;11:153–62.CrossRef
10.
go back to reference Slovin SF. Biomarkers for immunotherapy in genitourinary malignancies. Urol Oncol. 2016;34:205–13.CrossRef Slovin SF. Biomarkers for immunotherapy in genitourinary malignancies. Urol Oncol. 2016;34:205–13.CrossRef
11.
go back to reference Krpina K, Babarovic E, Dordevic G, Fuckar Z, Jonjic N. The association between the recurrence of solitary non-muscle invasive bladder cancer and tumor-infiltrating lymphocytes. Croat Med J. 2012;53:598–604.CrossRef Krpina K, Babarovic E, Dordevic G, Fuckar Z, Jonjic N. The association between the recurrence of solitary non-muscle invasive bladder cancer and tumor-infiltrating lymphocytes. Croat Med J. 2012;53:598–604.CrossRef
12.
go back to reference Baras AS, Drake C, Liu JJ, et al. The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. Oncoimmunology. 2016;5:e1134412.CrossRef Baras AS, Drake C, Liu JJ, et al. The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. Oncoimmunology. 2016;5:e1134412.CrossRef
13.
go back to reference Sjodahl G, Lovgren K, Lauss M, et al. Infiltration of CD3(+) and CD68(+) cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors. Urol Oncol. 2014;32:791–7.CrossRef Sjodahl G, Lovgren K, Lauss M, et al. Infiltration of CD3(+) and CD68(+) cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors. Urol Oncol. 2014;32:791–7.CrossRef
14.
go back to reference Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the “Immunoscore” in the classification of malignant tumours. J Pathol. 2014;232:199–209.CrossRef Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the “Immunoscore” in the classification of malignant tumours. J Pathol. 2014;232:199–209.CrossRef
15.
go back to reference Mlecnik B, Van den Eynde M, Bindea G, et al. Comprehensive intrametastatic immune quantification and major impact of Immunoscore on survival. J Natl Cancer Inst. 2018;110:97–108.CrossRef Mlecnik B, Van den Eynde M, Bindea G, et al. Comprehensive intrametastatic immune quantification and major impact of Immunoscore on survival. J Natl Cancer Inst. 2018;110:97–108.CrossRef
16.
go back to reference Jiang Y, Zhang Q, Hu Y, et al. ImmunoScore Signature: a prognostic and predictive tool in gastric cancer. Ann Surg. 2018;267:504–13.CrossRef Jiang Y, Zhang Q, Hu Y, et al. ImmunoScore Signature: a prognostic and predictive tool in gastric cancer. Ann Surg. 2018;267:504–13.CrossRef
17.
go back to reference Anitei MG, Zeitoun G, Mlecnik B, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res. 2014;20:1891–9.CrossRef Anitei MG, Zeitoun G, Mlecnik B, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res. 2014;20:1891–9.CrossRef
18.
go back to reference Tahkola K, Mecklin JP, Wirta EV, et al. High immune cell score predicts improved survival in pancreatic cancer. Virchows Arch. 2018;472:653–65.CrossRef Tahkola K, Mecklin JP, Wirta EV, et al. High immune cell score predicts improved survival in pancreatic cancer. Virchows Arch. 2018;472:653–65.CrossRef
19.
go back to reference Pages F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet Lond Engl. 2018;391:2128–39.CrossRef Pages F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet Lond Engl. 2018;391:2128–39.CrossRef
20.
go back to reference Ingels A, Sanchez Salas RE, Ravery V, et al. T-helper 1 immunoreaction influences survival in muscle-invasive bladder cancer: proof of concept. Ecancermedicalscience. 2014;8:486.CrossRef Ingels A, Sanchez Salas RE, Ravery V, et al. T-helper 1 immunoreaction influences survival in muscle-invasive bladder cancer: proof of concept. Ecancermedicalscience. 2014;8:486.CrossRef
21.
go back to reference Yu A, Mansure JJ, Solanki S, et al. Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+, CD8+, and immunoscore as prognostic marker in patients after radical cystectomy. PloS ONE. 2018;13:e0205746.CrossRef Yu A, Mansure JJ, Solanki S, et al. Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+, CD8+, and immunoscore as prognostic marker in patients after radical cystectomy. PloS ONE. 2018;13:e0205746.CrossRef
22.
go back to reference Marisa L, Svrcek M, Collura A, et al. The balance between cytotoxic t-cell lymphocytes and immune checkpoint expression in the prognosis of colon tumors. J Natl Cancer Inst. 2018;110:68–77.CrossRef Marisa L, Svrcek M, Collura A, et al. The balance between cytotoxic t-cell lymphocytes and immune checkpoint expression in the prognosis of colon tumors. J Natl Cancer Inst. 2018;110:68–77.CrossRef
23.
go back to reference Mlecnik B, Bindea G, Kirilovsky A, et al. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med. 2016;8: 327ra326.CrossRef Mlecnik B, Bindea G, Kirilovsky A, et al. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med. 2016;8: 327ra326.CrossRef
24.
go back to reference Gabrielson A, Wu Y, Wang H, et al. Intratumoral CD3 and CD8 T cell densities associated with relapse-free survival in HCC. Cancer Immunol Res. 2016;4:419–30.CrossRef Gabrielson A, Wu Y, Wang H, et al. Intratumoral CD3 and CD8 T cell densities associated with relapse-free survival in HCC. Cancer Immunol Res. 2016;4:419–30.CrossRef
25.
go back to reference Vayrynen JP, Vornanen JO, Sajanti S, Bohm JP, Tuomisto A, Makinen MJ. An improved image analysis method for cell counting lends credibility to the prognostic significance of T cells in colorectal cancer. Virchows Arch. 2012;460:455–65.CrossRef Vayrynen JP, Vornanen JO, Sajanti S, Bohm JP, Tuomisto A, Makinen MJ. An improved image analysis method for cell counting lends credibility to the prognostic significance of T cells in colorectal cancer. Virchows Arch. 2012;460:455–65.CrossRef
26.
go back to reference Yoon HH, Shi Q, Heying EN, et al. Intertumoral heterogeneity of CD3(+) and CD8(+) T cell densities in the microenvironment of DNA mismatch-repair-deficient colon cancers: implications for prognosis. Clin Cancer Res. 2019;25:125–33.CrossRef Yoon HH, Shi Q, Heying EN, et al. Intertumoral heterogeneity of CD3(+) and CD8(+) T cell densities in the microenvironment of DNA mismatch-repair-deficient colon cancers: implications for prognosis. Clin Cancer Res. 2019;25:125–33.CrossRef
27.
go back to reference Li XD, Chen SL, Dong P, et al. Overexpression of RNF2 is an independent predictor of outcome in patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Sci Rep. 2016;6:20894.CrossRef Li XD, Chen SL, Dong P, et al. Overexpression of RNF2 is an independent predictor of outcome in patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Sci Rep. 2016;6:20894.CrossRef
28.
go back to reference Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRef Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRef
29.
go back to reference Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2015;16:76–86.CrossRef Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2015;16:76–86.CrossRef
30.
go back to reference Streeper NM, Simons CM, Konety BR, et al. The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer. BJU Int. 2009;103:475–9.CrossRef Streeper NM, Simons CM, Konety BR, et al. The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer. BJU Int. 2009;103:475–9.CrossRef
31.
go back to reference Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99.CrossRef Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99.CrossRef
32.
go back to reference Spranger S, Gajewski TF. A new paradigm for tumor immune escape: beta-catenin-driven immune exclusion. J Immunother Cancer. 2015;3:43.CrossRef Spranger S, Gajewski TF. A new paradigm for tumor immune escape: beta-catenin-driven immune exclusion. J Immunother Cancer. 2015;3:43.CrossRef
33.
go back to reference Liu C, Peng W, Xu C, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013;19:393–403.CrossRef Liu C, Peng W, Xu C, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013;19:393–403.CrossRef
34.
go back to reference Lanaya H, Natarajan A, Komposch K, et al. EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. Nat Cell Biol. 2014;16:972–7.CrossRef Lanaya H, Natarajan A, Komposch K, et al. EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. Nat Cell Biol. 2014;16:972–7.CrossRef
35.
go back to reference Angelova M, Mlecnik B, Vasaturo A, et al. Evolution of metastases in space and time under immune selection. Cell. 2018;175:751–65.e716.CrossRef Angelova M, Mlecnik B, Vasaturo A, et al. Evolution of metastases in space and time under immune selection. Cell. 2018;175:751–65.e716.CrossRef
Metadata
Title
Prognostic Role of the Immunoscore for Patients with Urothelial Carcinoma of the Bladder Who Underwent Radical Cystectomy
Authors
Xiang-Dong Li, MD
Chao-Wen Huang, MD
Ze-Fu Liu, MD
Li-Juan Jiang, MD
Jie-Wei Chen, MD
Dan Xie, MD, PhD
Fang-Jian Zhou, MD, PhD
Hui-Ming Lu, MD
Zhuo-Wei Liu, MD, PhD
Publication date
01-11-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 12/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07529-y

Other articles of this Issue 12/2019

Annals of Surgical Oncology 12/2019 Go to the issue